BIOATLA INC (BCAB) Stock News

USA - NASDAQ:BCAB - US09077B1044 - Common Stock

0.8297 USD

+0.09 (+12.69%)

Last: 10/17/2025, 8:00:01 PM

0.8478 USD

+0.02 (+2.18%)

After Hours: 10/17/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BCAB Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Benzinga - Mentions: BCRX XNCR SNTI ADAP ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

15 days ago - By: BioAtla, Inc.

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

a month ago - By: Benzinga - Mentions: BLRX PRQR SXTC CNSP ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

2 months ago - By: The Motley Fool

BioAtla (BCAB) Q2 Loss Narrows 27%

2 months ago - By: BioAtla, Inc.

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

4 months ago - By: BioAtla, Inc.

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO)

6 months ago - By: BioAtla, Inc.

BioAtla to Participate in the Citizens Life Sciences Conference

6 months ago - By: BioAtla, Inc.

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

6 months ago - By: BioAtla, Inc.

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

6 months ago - By: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

a year ago - By: InvestorPlace

BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024

a year ago - By: BusinessInsider

News Image

BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024

a year ago - By: InvestorPlace

BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024

7 months ago - By: BioAtla, Inc.

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

7 months ago - By: BioAtla, Inc.

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

7 months ago - By: BioAtla, Inc.

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

10 months ago - By: BioAtla, Inc.

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

10 months ago - By: BioAtla, Inc.

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

10 months ago - By: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

a year ago - By: BioAtla, Inc.

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

a year ago - By: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

a year ago - By: BioAtla, Inc.

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

a year ago - By: Context Therapeutics Inc. - Mentions: CNTX

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

a year ago - By: BioAtla, Inc.

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

a year ago - By: BioAtla, Inc.

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

a year ago - By: BioAtla, Inc.

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress